AACR Appoints Patrice J. Morin, Ph.D., as Director of Scientific Review and Grants Administration
PHILADELPHIA — The American Association for Cancer Research welcomes Patrice J. Morin, Ph.D., as director of scientific review and grants administration. Morin, who has been actively involved in cancer research for more than 20 years, will be guiding the scientific review and administration of Stand Up To Cancer (SU2C) grants as well as other AACR grants.
“I am absolutely delighted that Pat Morin joined us as a member of the AACR senior staff. He is not only an active cancer researcher with enormous expertise in the field, but he also has strong administrative and organizational skills, and an affable personality that will facilitate his work as a team player and consensus builder,” said Margaret Foti, Ph.D., M.D. (h.c.), chief executive officer of the AACR. “His superb judgment and dedication are already making a difference in our grants program, and I look forward to seeing his future accomplishments. His work will undoubtedly benefit the AACR’s ever-increasing grants program.”
Morin received his doctorate in molecular biology from Boston University in 1995, and completed his undergraduate studies in biophysics at the University of Quebec, Canada, where he received his bachelor’s and master’s degree. He has had a robust career in research, with more than 80 publication credits to his name, and has been a longtime member of the AACR.
“The AACR has a long history of funding cutting-edge cancer research and it is a great honor for me to join the AACR as director of scientific review and grants administration. I look forward to working with the cancer research community to continue to expand our grants programs and develop new, innovative mechanisms for funding the most impactful research,” Morin said.
Prior to joining the AACR, Morin was a senior investigator in the Intramural Research Program of the National Institute on Aging at the National Institutes of Health (NIH). After joining the NIH in 1998, he developed a research program that was focused on elucidating the mechanisms of ovarian tumorigenesis. His group was one of the first to perform gene expression profiling in ovarian cancer, and in 2000 he first identified claudin proteins as being abnormally expressed in cancer. These findings led to research investigating the possible use of claudins in targeted therapies and in the detection of various cancers.
Before going to the NIH, Morin was affiliated with Johns Hopkins University Medical Center in Baltimore, Md. While there, he co-authored papers along with Drs. Bert Vogelstein and Ken Kinzler. In addition, he held an adjunct faculty position there from 1998 to the present.
Morin is a long-time member of the AACR. Having served as a grant reviewer on numerous study sections for both government and non-government agencies, he is an expert in the scientific peer review process and grants administration. In addition, for a number of years, he was an associate editor of the AACR’s journal, Cancer Research, and has served as a reviewer of more than 250 manuscripts submitted to various scientific journals. He has given many lectures in the field, chaired scientific symposia and is an acknowledged leader in the cancer field.
About the American Association for Cancer Research
Founded in 1907, the American Association for Cancer Research (AACR) is the world’s first and largest professional organization dedicated to advancing cancer research and its mission to prevent and cure cancer. AACR membership includes more than 34,000 laboratory, translational and clinical researchers; population scientists; other health care professionals; and cancer advocates residing in more than 90 countries. The AACR marshals the full spectrum of expertise of the cancer community to accelerate progress in the prevention, biology, diagnosis and treatment of cancer by annually convening more than 20 conferences and educational workshops, the largest of which is the AACR Annual Meeting with more than 17,000 attendees. In addition, the AACR publishes seven peer-reviewed scientific journals and a magazine for cancer survivors, patients and their caregivers. The AACR funds meritorious research directly as well as in cooperation with numerous cancer organizations. As the scientific partner of Stand Up To Cancer, the AACR provides expert peer review, grants administration and scientific oversight of team science and individual grants in cancer research that have the potential for near-term patient benefit. The AACR actively communicates with legislators and policymakers about the value of cancer research and related biomedical science in saving lives from cancer.
For more information about the AACR, visit www.AACR.org.